- 期刊
- OpenAccess
Clinical Utility of Treprostinil and Its Overall Place in the Treatment of Pulmonary Arterial Hypertension
並列摘要
Pulmonary arterial hypertension (PAH) is a disease that leads to characteristic vascular wall remodeling and hemodynamic alterations. Consequently, this pulmonary vascular disease contributes to substantial morbidity and mortality in afflicted patients. PAH may be idiopathic in nature or associated with connective tissue disease, chronic liver disease, human immunodeficiency virus, congenital heart disease, and a growing list of other conditions. There are currently nine Food and Drug Administration-approved therapies for specific PAH treatment. Therapeutic targets include prostacyclin replacement, endothelin-1 antagonism, and phosphodiesterase-5 inhibition. This article focuses on the prostanoid treprostinil and explores its role in the management of patients with PAH.
延伸閱讀
- 吳書豪、吳懿哲（2016）。Treatment Strategy and Response for Pulmonary Arterial Hypertension。台灣醫學，20(2)，167-176。https://doi.org/10.6320/FJM.2016.20(2).6
- Lin, C. L., Wu, M. H., Lai, W. W., Chen, C. W., Chang, H. Y., & Hsiue, T. R. (2005). Clinical Manifestations and Surgical Treatment Outcomes of Pulmonary Aspergilloma. 胸腔醫學, 20(5), 380-385. https://doi.org/10.29806/TM.200510.0004
- 鍾慧萱（2010）。Pharmacologic study of theophylline-based KMUP-1 on pulmonary artery hypertension〔博士論文，高雄醫學大學〕。華藝線上圖書館。https://www.airitilibrary.com/Article/Detail?DocID=U0011-1910201022354300
- Hung, C. C., Cheng, C. C., Huang, W. C., Lin, K. C., Kuo, F. Y., Kuo, S. H., Yang, T. H., Liang, H. L., & Mar, G. Y. (2020). Management of Pulmonary Arterial Hypertension Patients with World Health Organization Functional Class II. Acta Cardiologica Sinica, 36(6), 583-587. https://doi.org/10.6515/ACS.202011_36(6).20200507A
- 陳資濤、蘇健、吳健樑（2009）。Review of Pulmonary Arterial Hypertension Management。內科學誌，20(1)，19-29。https://doi.org/10.6314/JIMT.2009.20(1).02